Septerna (Nasdaq: SEPN) said CEO and co-founder Jeffrey Finer, M.D., Ph.D. will present at the Bank of America Securities Health Care Conference on May 12, 2026 at 5:00 p.m. PT in Las Vegas.
A live webcast will be available on the company investor site and archived for at least 30 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SEPN
-2.78%
5 alerts
-2.78%Session close to close
$1.06BMarket Cap
0.4xRel. Volume
In the May 5 session, SEPN declined 2.78%, reflecting a moderate negative market reaction.
Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
This announcement highlights a visibility event: Septerna’s CEO presenting at a major Bank of Americ...
Analysis
This announcement highlights a visibility event: Septerna’s CEO presenting at a major Bank of America health care conference on May 12, 2026, with a webcast archived for 30 days. Contextually, the company has recently advanced SEP-479 into Phase 1 and reported detailed SEP-631 data, while maintaining an effective $150,000,000 ATM facility. Investors may watch how management messaging at the conference ties into these clinical milestones and broader capital plans.
Planned presentation of Phase 1 SEP-631 data at AAAAI meeting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news often saw price moves aligned with the general tone, with one earnings-related divergence.
Recent Company History
Over the past few months, Septerna has combined clinical and corporate milestones. On Feb 10, it highlighted Phase 1 SEP-631 data and additional trial plans, followed by inducement option grants the same day. A Feb 24 conference presentation announcement saw a double‑digit gain. On Mar 9, earnings and pipeline progress coincided with a modest decline despite stronger revenue and narrowed losses. The Apr 13 SEP-479 Phase 1 initiation produced a small gain. Today’s Bank of America conference appearance continues this pattern of frequent investor-facing events.
Key Terms
g protein-coupled receptor, gpcr, webcast
3 terms
g protein-coupled receptormedical
"pioneering a new era of G protein-coupled receptor (GPCR) drug discovery"
A G protein-coupled receptor is a protein on a cell’s surface that acts like an antenna: it detects signals such as hormones, neurotransmitters or drugs outside the cell and passes that message inside to change cell behavior. Investors care because roughly a third of marketed medicines act on these receptors, so a company’s success in targeting or modulating a specific receptor can determine the value of drug candidates, regulatory risk, and future revenue potential.
gpcrmedical
"pioneering a new era of G protein-coupled receptor (GPCR) drug discovery"
G protein-coupled receptors (GPCRs) are a large family of proteins on cell surfaces that act like locks sensing chemical signals — when the right key binds, they trigger internal cell responses. They matter to investors because GPCRs are the target of many marketed drugs and experimental therapies; success or failure in developing a GPCR-targeting drug can change a company’s revenue prospects, clinical progress, and licensing value, much like winning control of a widely used distribution channel.
webcasttechnical
"A live webcast of the presentation will be available in the investors section"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the Bank of America Securities Health Care Conference on Tuesday, May 12, 2026, at 5:00 p.m. PT in Las Vegas.
A live webcast of the presentation will be available in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation.
About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
When will Septerna (SEPN) present at the Bank of America Health Care Conference?
Septerna will present on May 12, 2026 at 5:00 p.m. PT. According to Septerna, CEO Jeffrey Finer will deliver the presentation in Las Vegas; a live webcast is planned for investors who cannot attend in person.
How can investors watch Septerna's (SEPN) Bank of America conference presentation?
Investors can watch a live webcast on the company's investor website. According to Septerna, the webcast will be available at www.septerna.com and archived for at least 30 days after the presentation for later viewing.
Who from Septerna (SEPN) will present at the May 2026 conference?
Jeffrey Finer, M.D., Ph.D., CEO and co-founder of Septerna, will present. According to Septerna, Dr. Finer will discuss the company's clinical-stage GPCR drug discovery programs during the Bank of America Health Care Conference.
Will Septerna (SEPN) make new clinical disclosures at the Bank of America conference?
The announcement confirms a presentation but does not list specific new clinical data. According to Septerna, the CEO will present at the conference; investors should watch the webcast for any program updates or disclosures.
How long will Septerna's (SEPN) conference webcast remain available after May 12, 2026?
The webcast will be archived for at least 30 days following the presentation. According to Septerna, investors can access the archived webcast on the company investor website for that minimum period after the live event.
